Clinical trials: Liver Cancer
Hepatocellular Carcinoma
Chemoembolization for Hepatocellular Carcinoma
The aim of the current study is to study the safety and effectiveness of TACE using a high dose of cisplatin for treatment of HCC.
- Trial name
- NCT02821533
- Testing
- TACE, Cisplatin
- Where
- Hong Kong
- Volunteers
- 24 people
- Sponsor
- Chinese University of Hong Kong
Liver Neoplasm, Kidney Injury, Acute
Perioperative Myocardial and Renal Injury in Patients Undergoing Hepatic Resection
Liver surgeries are high risk surgeries that might result in injuries in kidneys and heart. This study was planned to investigate the frequency of these injuries as well as the risk factors for their devolopment and its effect on…
- Conditions
- Liver Neoplasm, Kidney Injury, Acute, Myocardial Injury After Non-Cardiac Surgery
- Trial name
- NCT06775158
- Where
- Turkey (Türkiye)
- Volunteers
- 128 people
- Sponsor
- Istanbul Saglik Bilimleri University
Diabetes, Chronic Kidney Diseases
Benchtop NMR Spectroscopy for Assessment of Clinical Human Pathologies (BRANCH-P STUDY)
This research programme seeks to combine the resources of NHS primary care, with the leading spectroscopic work in low-magnetic fields of the Wilson Group (Nottingham Trent University) to demonstrate the potential for benchtop…
- Conditions
- Diabetes, Chronic Kidney Diseases, Cancer, Bowel Disease
- Trial name
- BRANCH-P (NCT05473325)
- Where
- United Kingdom
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Willows Health
Hepatocellular Carcinoma (HCC)
Effect of Biejia-Ruangan Compound on Survival Rate and Recurrence Rate of Hepatocellular Carcinoma After Radical Treatment
This study plans to enroll 704 patients with a history of chronic hepatitis B who have undergone radical treatment for hepatocellular carcinoma.
- Trial name
- BRCSRRRHCCART (NCT06923176)
- Testing
- Biejia-Ruangan compound, Routine medical care
- Volunteers
- 704 people
- Sponsor
- Zhiyun Yang
Colorectal Cancer, Liver Metastasis Colon Cancer
Fluorescence-guided Resection Of Colorectal Liver Metastases Using SGM-101 and Indocyanine GREEN
This will be the first trial testing the feasibility of working simultaneously with the two fluorescent dyes ICG and SGM-101 in 10 patients with colorectal metastases.
- Conditions
- Colorectal Cancer, Liver Metastasis Colon Cancer, Image
- Trial name
- FOCUS GREEN (NCT05965817)
- Testing
- SGM-101 op top of ICG
- Where
- Netherlands
- Volunteers
- 10 people
- Sponsor
- Leiden University Medical Center
Hepatic Carcinoma
Percutaneous Irreversible Electroporation for Unresectable Hepatic Carcinoma in Poor Liver Function
The purpose of this study is to investigate the safety and efficacy of irreversible electroporation for unresectable Hepatic carcinoma in poor liver function, also Progress Free Survival (PFS) and Over Survival (OS) will be…
- Trial name
- NCT02352935
- Testing
- NanoKnife LEDC System
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Fuda Cancer Hospital, Guangzhou
Hepatocellular Carcinoma
Study of TG02 Citrate in Patients With Advanced Hepatocellular Carcinoma
This is a single-centre, open-label, dose escalation, Phase 1 study. The primary objective is to determine the highest dose of TG02 citrate that can safely be given to patients with advanced hepatocellular carcinoma.
- Trial name
- NCT03738111
- Testing
- TG02 Citrate
- Sponsor
- Lee's Pharmaceutical Limited
Hepatocellular Carcinoma
A Clinical Trial to Compare the Pharmacokinetics and Bioequivalence of "BR2008" With "BR2008-1" in Healthy Volunteers
A clinical trial to compare the pharmacokinetics and bioequivalence of BR2008 with BR2008-1 in healthy volunteers
- Trial name
- NCT05068193
- Testing
- BR2008-1 (R), BR2008 (T)
- Where
- South Korea
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Hepatocellular Carcinoma
A Phase 1 Study of MM-141 in Patients With Advanced Solid Tumors
This study is a Phase 1 and pharmacologic open-labeled dose-escalation trial using a "3+3" design, evaluating MM-141 at varying dose levels and frequencies.
- Trial name
- NCT01733004
- Testing
- MM-141
- Where
- 4 sites in United States, France
- Volunteers
- 42 people
- Sponsor
- Merrimack Pharmaceuticals
Hepatocellular Carcinoma (HCC)
TACE and/or HAIC Combined With Molecular-targeted Therapy and Immunotherapy for HCC
The safety, clinical efficacy and prognostic factors of transcatheter arterial chemoembolization (TACE) and/or hepatic artery infusion chemotherapy (HAIC) combined with targeted immunotherapy for primary hepatocellular carcinoma…
- Trial name
- NCT07658833
- Testing
- TACE (transarterial chemoembolization) combined with targeted/immunotherapy
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Hepatocellular Carcinoma
Efficacy of Sequential TACE and PVE on the Resectability of Hepatitis B Related HCC
A primary hepatocellular carcinoma (HCC) is generally regarded as unresectable if the future liver remnant (FLR)≤40％ of total liver volume in patient with underlying liver disease, such as hepatitis B.
- Trial name
- TACEPVE (NCT00834158)
- Testing
- TACE, PVE
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Solid Tumor, Solid Carcinoma
Trop2-targeted immunoPET Imaging of Solid Tumors
This study aims to establish and optimize the trophoblast cell surface antigen 2 (Trop2)-targeted immuno-positron emission tomography/computed tomography (immunoPET/CT) imaging method and its physiological and pathological…
- Conditions
- Solid Tumor, Solid Carcinoma, Uroepithelial Carcinoma, Bladder Cancer
- Trial name
- NCT06851663
- Testing
- [68Ga]Ga-NOTA-T4, [68Ga]Ga-NOTA-RT4, [18F]F-RESCA-T4
- Where
- China
- Volunteers
- 400 people
- Sponsor
- RenJi Hospital
Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer
Veliparib, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Biliary, Pancreatic, Urothelial, or Non-Small Cell Lung Cancer
This phase I clinical trial is studying the side effects and best dose of veliparib and gemcitabine hydrochloride when given with cisplatin in treating patients with advanced biliary, pancreatic, urothelial, or non-small cell…
- Conditions
- Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Regional Transitional Cell Cancer of the Renal Pelvis and Ureter
- Trial name
- NCT01282333
- Testing
- gemcitabine hydrochloride, veliparib, diagnostic laboratory biomarker analysis
- Where
- 3 sites in United States
- Volunteers
- 44 people
- Sponsor
- National Cancer Institute (NCI)
Hepatic Metastasis of Colorectal Cancer
Camrelizumab Combined With Apatinib 、XELOX 、RFA in the Treatment of Liver Metastases of Colorectal Cancer
To evaluate the safety of karillizumab combined with apatinib mesylate, XELOX and radiofrequency ablation
- Trial name
- NCT04202978
- Testing
- Camrelizumab, Apatinib Mesylate, Capecitabine
- Where
- China
- Volunteers
- 23 people
- Sponsor
- Zhongshan Hospital Xiamen University
Cancer, Metastases
Gadofosveset Trisodium (Ablavar, Gdfos) in Distinguishing Hemangiomas and Metastases: A Prospective Trial
The purpose of this study is to determine if Gadofosveset Trisodium (Gdfos, Ablavar) is a useful magnetic resonance imaging (MRI) contrast agent in accurately diagnosing liver metastases compared to the standard agent gadobutrol…
- Conditions
- Cancer, Metastases, Liver Neoplasms
- Trial name
- NCT02036008
- Testing
- Liver MRI with Gdfos, Liver MRI with EcGd
- Where
- Canada
- Volunteers
- 150 people
- Sponsor
- Sunnybrook Health Sciences Centre
Hepatocellular Carcinoma
Ablation Combined With PD-1 in HCC: Phase II Study
This is a Phase 2, single arm, single center study designed to evaluate the safety and tolerability of radiofrequency or microwave ablation combined with PD-1 monoclonal antibody in patients with hepatocellular carcinoma(HCC)…
- Trial name
- NCT04652440
- Testing
- PD-1 monoclonal antibody, Radiofequencey or microwave ablation
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sun Yat-sen University
Infection
Telaprevir Plus Standard of Care (SOC) in HCV Associated Hepatocellular Carcinoma (HCC)
The goal of this clinical research study is to learn if the antiviral combination of telaprevir, pegylated Interferon Alfa 2a (PegIFN alfa-2a) and ribavirin (RBV) can prevent the virus from coming back after the liver transplant.
- Trial name
- NCT01821963
- Testing
- Pegylated Interferon Alfa 2a, Ribavirin, Telaprevir
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- M.D. Anderson Cancer Center
Hepatocellular Carcinoma, Microwave Ablation
Donafenib as Adjuvant Therapy Following Ablation for Recurrent HCC
This study intends to evaluate the efficacy and safety of low-dose adjuvant donafenib after thermal ablation for early recurrent HCC within Milan criteria.
- Conditions
- Hepatocellular Carcinoma, Microwave Ablation, Donafenib, Recurrent Tumor
- Trial name
- NCT06609876
- Testing
- Thermal ablation, Donafenib
- Where
- China
- Volunteers
- 108 people
- Sponsor
- Sun Yat-sen University
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer
3-Tesla MRI Response to TACE in HCC (Liver Cancer)
This pilot clinical trial examines how well different imaging biomarkers acquired using 3-Telsa magnetic resonance imaging (MRI) methods perform in determining treatment response to transarterial chemoembolization (TACE) in…
- Conditions
- Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Resectable Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer
- Trial name
- NCT02057874
- Testing
- 3 Tesla Magnetic Resonance Imaging, Magnevist® (Intravenous (IV) administration of MRI contrast agent)
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Advanced Hepatocellular Carcinoma (HCC), Metastatic Liver Cancer
Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC
open-label trial of an allogeneic dual-target CAR-NK product directed against GPC3 and B7-H3 for adults with advanced hepatocellular carcinoma.
- Trial name
- DUET-HCC (NCT07500220)
- Testing
- EB-G3B7-NK dual-target CAR-NK cells, Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Beijing Biotech